VY-201: Multi-Antigen Engager Program
Leveraging the advantages of its VY-GAGE tumor-specific, multi-antigen engager platform, Vycellix is advancing VY-201 as its first VY-GAGE product candidate designed to more effectively target solid tumors.
VY-201 is believed to overcome the challenges most often associated with bispecific engagers including:
- Treatment toxicity
- Treatment resistance
- Frequent dosing requirements
